Peptide YY inhibition of prostaglandin-induced intestinal secretion is haloperidol-sensitive in humans

What Was Tested

This randomized controlled trial paper looks at Peptide YY.

It is uncertain whether peptide YY (PYY) inhibits human intestinal secretion directly through enterocyte receptors or via indirect neural mechanisms.

Thus, the effect of PYY on prostaglandin E2 (PGE2)-induced jejunal secretion in normal volunteers was measured, and it was determined whether a dopamine and sigma antagonist affected PYY effect.

Who Took Part

The study group was 6 volunteers.

Jejunal absorption of water and electrolytes was measured by a perfusion method in 6 volunteers.

How the Study Was Run

The researchers set it up as a randomized, double-blind, placebo-controlled and crossover study.

The volunteers were allocated by chance, so the Peptide YY group and the comparison group should start out alike.

As a double-blind Peptide YY study, the assignments were hidden from both participants and investigators until the end.

The comparison arm used a placebo, so changes seen with Peptide YY could be set against what happens without it.

Each person switched between Peptide YY and the comparison at some point, usually with a gap in between.

A double-blind crossover study was performed, involving intraluminal infusion of PGE2, intravenous infusion of human PYY, and intramuscular injection of haloperidol or placebo.

What Was Measured

The subject headings attached to it are Dinoprostone, Dopamine Antagonists, Eating, Electrolytes, Haloperidol, Jejunum and Peptide YY.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Peptide YY in 6 volunteers.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 1997 (Gastroenterology), a journal based in United States.

More context: the Peptide YY compound page, all human trials.